The State Enterprise "Medical Procurements" is set to produce groundbreaking medications for cancer treatment.

According to the press service, a collaboration agreement with the international pharmaceutical company Roche was signed during the Ukraine Recovery Conference 2025 in Rome.

"This marks a significant milestone for our state enterprise as we partner with a global leader in innovative drug development. Under this investment agreement, Roche will supply medicines to Ukraine in bulk, and we will handle their final packaging and delivery to patients," the statement reads.

This initiative is expected to lower the cost of medications and increase the number of patients receiving modern treatments.

"According to Roche's estimates, over the next 5 years, this investment agreement will provide medications for more than 5,800 patients," added the State Enterprise "Medical Procurements".

The focus will be on procuring medications for the two most common types of cancer in Ukraine:

- Atezolizumab (“Tecentriq”) for the treatment of non-small cell lung cancer;

- Pertuzumab + Trastuzumab (“Phesgo”) for treating HER2-positive breast cancer.

The first Ukrainian patients will access these locally produced medications by 2027.

This collaboration promises significant reductions in drug costs, the growth of pharmaceutical manufacturing in Ukraine, and sustained access to treatment.

The fourth International Conference on Ukraine Recovery (URC2025) is taking place in Rome on July 10-11, featuring participation from the President of Ukraine and heads of European states.

This forum continues a series of high-level political events dedicated to the swift recovery and long-term reconstruction of Ukraine, which is currently facing external aggression. This time, the Ukrainian delegation focuses on presenting practical projects already underway or ready for implementation even amid war conditions.